(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 March 2006 (09.03.2006)

PCT

(10) International Publication Number
WO 2006/024944 A3

(51) International Patent Classification:
A61K 9/16 (2006.01) *A61K 31/505* (2006.01)
A61K 31/496 (2006.01) *A61K 9/26* (2006.01)

(21) International Application Number:
PCT/IB2005/002704

(22) International Filing Date: 18 August 2005 (18.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/606,178 31 August 2004 (31.08.2004) US

(71) Applicant *(for all designated States except US)*: **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **APPEL, Leah, Elizabeth** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **BABCOCK, Walter, Christian** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **FRIESEN, Dwayne, Thomas** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **RAY, Roderick, Jack** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **SHAMBLIN, Sheri, Lynn** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **SHANKER, Ravi, Mysore** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **SMITHEY, Daniel, Tod** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US).

(74) Agent: **FULLER, Grover, F.**; c/o Ruddock, Keith, S., Pfizer Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
24 August 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL DOSAGE FORMS COMPRISING A LOW-SOLUBILITY DRUG AND A POLYMER

(57) Abstract: A dosage form comprises a low-solubility drug, and a precipitation-inhibiting polymer. The drug is in a solubility-improved form and in the form of particles at least partially coated with the precipitation-inhibiting polymer. Exemplified low-solubility drugs are ziprasidone and sildenafil. Exemplified precipitation-inhibiting polymer is HPMCAS.

WO 2006/024944 A3